Covid-19: Doctors Hospital at Renaissance Responded to the Pandemic Surges

Doctors Hospital at Renaissance

A physician-owned hospital on the Texas-Mexico border responded to the Covid-19 surges.


Responding to the Covid-19 Crisis

Doctors Hospital at Renaissance stepped up when the community needed their help during several Covid-19 surges

“The effects of hospital consolidation on patients are very real. Given the pandemic-induced hospital bed shortage, one physician-owned community hospital near the Texas border, Doctors Hospital Renaissance, rapidly stood up dedicated Covid-19 units, eventually converting its rehabilitation hospital into a dedicated Covid-19 hospital with more than 100 beds in under 10 days. Such is the product of physician-driven innovation — out of necessity — in care delivery.”

The Rio Grande Valley Collaborative to Respond to Covid-19

A physician-owned hospital created a regional response to address Covid-19 in March 2020.

DHR Health established a collaborative with 11 regional hospitals on March 23, 2020, to provide convalescent plasma to area hospitals, share information, discuss best practices and identify efforts to address Covid-19 in the Rio Grande Valley.

DHR Health was the first in the region to initiate monoclonal antibody fusion in Covid-19 positive patients in November 2020.

Click here to learn more.

“DHR Health Wins Praise for Mass Vaccination Event”

A physician-owned hospital made it a priority to provide vaccinations to the community in the early days of the vaccination roll-out.

““DHR has organized all of this. I was asked to help organize the medical volunteers and I can say without a doubt that this has been the best run, best organized event I have ever done for the community.”

Click here to read the full story from January 22, 2021.

DHR Health Offers Antibody Treatment for Omicron Variant

DHR Health Institute for Research and Development is offering the only treatment currently available to prevent infection by the Omicron variant.

Doctors Hospital at Renaissance announced on January 26, 2022, that it is offering the only treatment currently available to prevent infection by the Omicron variant of SARS-CoV-2.